Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.30 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.30 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.30 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.30 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21484162 | 0.81 | CREBBP (0.34) | CREBBPHTTDPP4DPP7BMPR1B | |
| SCHEMBL21484165 | 0.79 | PTGS2 (0.37) | HSD11B1CYP2C19CYP2C9NPY5RBMPR1B | |
| SCHEMBL12217560 | 0.71 | CREBBP (0.42) | CREBBPHTTBMPR1BBMPR1AACVRL1 | |
| SCHEMBL21476022 | 0.71 | PTGS2 (0.35) | HSD11B1CYP2C19CYP2C9BMPR1BBMPR1A | |
| SCHEMBL24665804 | 0.69 | CREBBP (0.38) | CREBBPCYP2C9 | |
| SCHEMBL27369130 | 0.69 | MGLL (0.43) | CREBBPHTT | |
| SCHEMBL22757287 | 0.67 | HRH3 (0.43) | CREBBPDPP4DPP7 | |
| SCHEMBL16190092 | 0.64 | NPY5R (0.39) | CREBBPNPY5RBMPR1BBMPR1AACVRL1 | |
| SCHEMBL20148737 | 0.63 | RET (0.39) | CREBBPHSD11B1DPP4DPP7 | |
| SCHEMBL22812251 | 0.63 | RET (0.41) | CREBBPHSD11B1HTTBMPR1BBMPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174228-B2 | Antagonists of human integrin (α4)(β7) | MORPHIC THERAPEUTIC, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20200385352-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174228-B2 | Antagonists of human integrin (α4)(β7) | ITGB7, ITGB4, ITGA4 | CREBBP 4108/4885HSD11B1 3581/4885CYP3A4 2115/4885 |
| US-20200385352-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | CREBBP 4161/4885HSD11B1 3073/4885CYP3A4 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.